🔗 Visit the ClinicalTrials.gov page for NCT00694161
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. | Circ Heart Fail | 2015 | 0.95 |
| 2 | Functional Amyloid Signaling via the Inflammasome, Necrosome, and Signalosome: New Therapeutic Targets in Heart Failure. | Front Cardiovasc Med | 2015 | 0.79 |
| 3 | Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. | Neurol Ther | 2016 | 0.77 |
| 4 | Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. | J Cardiovasc Transl Res | 2015 | 0.75 |